- Home
- / ImmuPharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ImmuPharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
£0
2024-10-29
Market Capitalization
£6.6 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 81.0K | 78.0K | 127.0K | 118.0K | |||
| Gross profit | 81.0K | 198.0K | 127.0K | 118.0K | 119.0K | 9.0K | |
| Gross profit margin, % | 100.0% | 253.8% | 100.0% | 100.0% | |||
| Operating expense total | 8.0M | 6.9M | 5.5M | 6.6M | 2.9M | 3.1M | 2.2M |
| Depreciation and amortization | 133.0K | 90.0K | 171.0K | 114.0K | 118.0K | 38.0K | 457.0K |
| EBITDA | (7.9M) | (6.7M) | (5.4M) | (6.5M) | (2.9M) | (3.0M) | (2.2M) |
| EBITDA margin, % | -9811.1% | -8609.0% | -4266.1% | -5485.6% | |||
| EBIT | (8.1M) | (6.8M) | (5.6M) | (6.6M) | (3.0M) | (3.1M) | (2.7M) |
| EBIT margin, % | -9975.3% | -8724.4% | -4400.8% | -5582.2% | |||
| Interest income | 12.0K | 6.0K | 41.0K | 1.0K | 1.0K | 2.0K | 6.0K |
| Interest expense | 4.0K | 4.0K | 437.0K | 206.0K | 221.0K | 2.0K | 1.0K |
| Pre tax profit | (8.0M) | (6.7M) | (7.2M) | (8.9M) | (4.5M) | (3.4M) | (2.8M) |
| Income tax expense | (748.0K) | (621.0K) | (386.0K) | (767.0K) | (649.0K) | (497.0K) | (296.0K) |
| Net Income | (7.2M) | (6.1M) | (6.9M) | (8.2M) | (3.8M) | (2.9M) | (2.5M) |